True North Clinical Research

Providing Hope to Present and Future Generations

True North Clinical Research is committed to the health and wellness of patients living in Nova Scotia.

Why Clinical Research?

Clinical trials are an essential part of the research and development of all pharmaceutical drugs. All medication, whether sold through prescription or over-the-counter, must undergo comprehensive testing to ensure they treat the condition or conditions they were designed and created to treat without significant risk to those taking them.

Each and every trial we conduct is done so under strict guidelines, which are monitored by Health Canada. Health Canada approves the use of investigational medications within clinical trials, before these medications are approved for use by the general public. A Principal Investigator – a medical doctor trained to conduct research trials in a safe, ethical and controlled manner – oversees each of our research trials.

In order to qualify for a trial, participants are screened and must meet a strict criteria. Those participants who qualify to enroll in a trial will be required to attend a variety of appointments and their progress will be carefully tracked. During these visits, participants will work with our clinical staff and investigators. These visits could potentially include questionnaires, blood collection, physical exams, and diagnostic tests.

It should be noted that each participant is fully educated as to what to expect prior to undergoing any trial-related assessments that may be required.

Importance and Benefits of Participation
  • Contribution to the future development of medications worldwide
  • Access to potential treatment options that is currently not available to the general public
  • Constant monitoring and care provided by highly trained professionals
  • On-going support provided by clinical research staff
True North Clinical Memory and Alzheimer Conditions
How do I learn more?
If you are interested in learning more about clinical trials, or wish to inquire about out current or future trials, click here to contact us and one of our highly trained staff will be in touch to provide more information.

Recruiting Clinical Trials

Currently Recruiting New Participants
Alzheimer’s Disease – Green Memory – GV971-007

True North Clinical Research is currently involved in a phase 3 clinical trial with Shanghai Greenvalley Pharmaceutical Co., LTD to study the efficacy and safety of GV-971 for the treatment of Mild to Moderate Alzheimer’s Disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who are between the ages of 50 to 85 and have mild to moderate AD.

The study will run for approximately 78 weeks. Participants who qualify for this study and agree to participate will receive a daily dose of either the treatment or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.

Alzheimer’s Disease – INVOKE-2- AL002-2

True North Clinical Research is currently involved in a phase 2 clinical trial with Alector Inc., to study the efficacy and safety of AL002 for the treatment of early Alzheimer’s Disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well known cognitive test scores) of the study drug in patients who are between the ages of 50 to 85 and have AD.

The study will run for approximately 96 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks, of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.

Alzheimer’s Disease – Trailblazer-ALZ 2 – I5T-MC-AACI

True North Clinical Research is currently involved in a phase 2 clinical trial with Eli Lilly and Company, to study the efficacy and safety of their investigational drug for the treatment of early Alzheimer’s Disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience -known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well-known cognitive test scores) of the study drug in patients who are between the ages of 60 to 85 and have early AD.

The study will run for approximately 76 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.

Alzheimer’s Disease – Vielight Neuro RX Gamma – P17.03


True North Clinical Research is currently involved in a clinical trial with Vielight Inc. to study the feasibility, efficacy, and safety of the Vielight Neuro RX Gamma Device for the treatment of moderate to severe Alzheimer’s Disease (AD). The Neuro RX Gamma system is a headset which emits pulsed, near-infrared energy asynchronously through diodes placed on the scalp and inside a nostril.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the device improves symptoms and how it changes disease progression based on well-known cognitive test scores) in patients with Alzheimer’s Disease who are 50 years of age or older.

The study will run for approximately 12 weeks. Participants who qualify for this study and agree to participate will be provided either the Neuro RX Gamma sham device (placebo) or the Neuro RX Gamma active device. The device is to be used for 20-minute sessions 6 days a week at home. There will also be regular follow up visits in the clinic to monitor your health and safety. Participation in the study is voluntary, and participants may withdraw at any time.

Alzheimer’s disease – AHEAD 3-45 – BAN2401-G000-303

True North Clinical Research is currently involved in the AHEAD study, a phase 3 clinical trial with Eisai Inc., to study the efficacy and safety of BAN2401 (Iecanemab), for the investigational treatment of Preclinical Alzheimer’s disease (AD). For clarification, this means the participant is not showing any symptoms of AD.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience-known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on well-known cognitive test scores) of the study drug in patients who are between the ages of 55 to 80.

The study will run for approximately 216 weeks (4 years). Participants who qualify for this study will agree to receive intravenous infusions of the investigational treatment, of either the treatment or placebo (a salt water solution without the active drug). Participation in the study is voluntary, and participants can withdraw at any time.

This study is only recruiting at our New Minas location, Halifax will not be participating in this trial.

Ongoing Clinical Trials

Recruitment Closed

ANAVEX2-73

True North Clinical Research is currently involved in a phase 2b/3 clinical trial with Anavex Life Sciences Corp. researching an investigational drug for treatment of Early Alzheimer’s Disease (AD) called ANAVEX2-73 (versus a placebo; a treatment that looks like the study drug but is not).

ANAVEX2-71 is an investigational study drug which is being studied in people in who have early AD with mild cognitive (thinking) impairment or mild dementia. This investigational drug is also being studied with patients who have Rett’s Syndrome and for those Parkinson’s Disease and Dementia, however True North is only involved with the study for those with AD at this time.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.

The study will run for approximately 48 weeks. Participants who qualify for this study and agree to participate will receive a daily dose of either the treatment or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.

Clarity AD

True North Clinical Research is currently involved in a clinical trial with Eisai Co., Ltd. (known as “Eisai”) researching an investigational drug for early Alzheimer’s disease (AD) called BAN2401.

BAN2401 is what is known as a monoclonal antibody.  Antibodies are proteins produced by the immune system that bind to foreign substances in the body called antigens.  BAN2401 binds to amyloid in the brain in patients with AD and has been shown to reduce the amount of this abnormal protein.  In a different study, BAN2401 slowed the decline in cognition in some people. 

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.

Biogen (redosing)

True North Clinical Research is involved in an open-label study to determine the long-term safety and efficacy of a medication (called aducanumab) in patients who were part of previous studies on that same medication. Aducanumab is an antibody that targets amyloid, a protein that builds up in the brains of people with Alzheimer’s disease. 

These studies were originally discontinued based on the belief that the medication didn’t slow the progression of Alzheimer’s disease sufficiently. A re-examination of the data by Biogen (the developer) indicated that those receiving higher doses of the medication showed slower cognitive and functional decline versus those receiving lower doses or the placebo. 

Those involved in this current study must have taken part in one of the previous studies.

Marguerite Road

With Hoffman-La Roche, True North Clinical Research is involved in a clinical trial researching gantenerumab in patients with mild Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Scarlet Road

True North Clinical Research is involved in a clinical trial with Hoffman-La Roche, researching gantenerumab in patients with prodromal Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Buena

True North Clinical Research is involved in a clinical trial with IntelGenX, researching an investigational medication vs placebo in those with mild-moderate Alzheimer’s disease. The investigational medication being studied is a repurposed drug that is already on the market (Montelukast) and the sponsor is looking at the potential of this drug to reduce neuroinflammation in an effort to slow down the progression of memory loss due to Alzheimer’s disease. Participants must already be taking an acetylcholinesterase inhibitor such as Aricept in order to qualify to participate in the trial. This trial is evaluating the relationship between the investigational medication and the cognitive abilities of participants over a 26 week period.

Completed Clinical Trials

True North Clinical Research has proudly participated in many trials that have the potential to impact the lives of hundreds of thousands of people around the globe. Below is a list of some of our completed trails.